Physician profile
Karen Millender
NPI 1841392677
$1,086.14
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $500.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $302.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $186.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.89 | 2019-2020 | |
| Novo Nordisk INC | $84.51 | 2019-2020 | |
| Pfizer INC. | $80.18 | 2019-2020 | |
| Allergan, INC. | $62.43 | 2019-2020 | |
| Glaxosmithkline, LLC. | $44.56 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.40 | 2019-2020 | |
| Lilly USA, LLC | $32.57 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.41 | 2019 | |
| Amgen INC. | $18.65 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.25 | 2019 | |
| Abbvie INC. | $14.30 | 2019 | |
| Eisai INC. | $14.26 | 2019 | |
| Astellas Pharma US INC | $13.87 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.12 | 2020 | |
| Ibsa Pharma INC. | $11.18 | 2020 | |
| Merck Sharp & Dohme LLC | $11.13 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Millender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.